{"Abstract": [0], "Cancer": [1], "development": [2, 203], "and": [3, 31, 48, 71, 81, 95, 107, 125, 136, 150, 169, 195, 204], "its": [4], "response": [5], "to": [6, 52, 174], "therapy": [7], "are": [8], "regulated": [9], "by": [10], "inflammation,": [11, 198], "which": [12], "either": [13], "promotes": [14], "or": [15], "suppresses": [16], "tumor": [17, 29, 96, 202], "progression,": [18], "potentially": [19], "displaying": [20], "opposing": [21], "effects": [22], "on": [23], "therapeutic": [24], "outcomes.": [25], "Chronic": [26], "inflammation": [27, 177, 214], "facilitates": [28], "progression": [30], "treatment": [32, 217], "resistance,": [33], "whereas": [34], "induction": [35], "of": [36, 44, 73, 147, 152, 183, 197, 218], "acute": [37], "inflammatory": [38, 86, 130, 205], "reactions": [39], "often": [40], "stimulates": [41], "the": [42, 148, 193, 199, 216], "maturation": [43], "dendritic": [45], "cells": [46], "(DCs)": [47], "antigen": [49], "presentation,": [50], "leading": [51], "anti-tumor": [53], "immune": [54], "responses.": [55], "In": [56], "addition,": [57], "multiple": [58], "signaling": [59], "pathways,": [60, 79], "such": [61], "as": [62, 127, 129, 144], "nuclear": [63], "factor": [64, 98, 119, 123], "kappa": [65], "B": [66], "(NF-kB),": [67], "Janus": [68], "kinase/signal": [69], "transducers": [70], "activators": [72], "transcription": [74], "(JAK-STAT),": [75], "toll-like": [76], "receptor": [77], "(TLR)": [78], "cGAS/STING,": [80], "mitogen-activated": [82], "protein": [83], "kinase": [84], "(MAPK);": [85], "factors,": [87], "including": [88, 132], "cytokines": [89], "(e.g.,": [90, 101, 115], "interleukin": [91], "(IL),": [92], "interferon": [93], "(IFN),": [94], "necrosis": [97], "(TNF)-\u03b1),": [99], "chemokines": [100], "C-C": [102], "motif": [103, 109], "chemokine": [104, 110], "ligands": [105, 111], "(CCLs)": [106], "C-X-C": [108], "(CXCLs)),": [112], "growth": [113, 118, 122], "factors": [114, 185], "vascular": [116], "endothelial": [117], "(VEGF),": [120], "transforming": [121], "(TGF)-\u03b2),": [124], "inflammasome;": [126], "well": [128], "metabolites": [131], "prostaglandins,": [133], "leukotrienes,": [134], "thromboxane,": [135], "specialized": [137], "proresolving": [138], "mediators": [139], "(SPM),": [140], "have": [141, 171], "been": [142, 172], "identified": [143], "pivotal": [145], "regulators": [146], "initiation": [149, 194], "resolution": [151, 196], "inflammation.": [153], "Nowadays,": [154], "local": [155], "irradiation,": [156], "recombinant": [157], "cytokines,": [158], "neutralizing": [159], "antibodies,": [160], "small-molecule": [161], "inhibitors,": [162], "DC": [163], "vaccines,": [164], "oncolytic": [165], "viruses,": [166], "TLR": [167], "agonists,": [168], "SPM": [170], "developed": [173], "specifically": [175], "modulate": [176], "in": [178, 215], "cancer": [179], "therapy,": [180], "with": [181], "some": [182], "these": [184], "already": [186], "undergoing": [187], "clinical": [188], "trials.": [189], "Herein,": [190], "we": [191], "discuss": [192], "crosstalk": [200], "between": [201], "processes.": [206], "We": [207], "also": [208], "highlight": [209], "potential": [210], "targets": [211], "for": [212], "harnessing": [213], "cancer.": [219]}